BNOAT Oncology, Inc. is a drug discovery and development company founded by renowned biochemist, Dr. Joseph A. Bauer, a Professional Staff Alumnus of the Cleveland Clinic Foundation (ranked top 4 in the United States by US News & World Report).
BNOAT Oncology, Inc. specializes in one-carbon metabolism and nitric oxide donor chemistry. BNOAT’s proprietary synthesis methods have resulted in the first-ever bulk synthesis of a nitric oxide donor compound. BNOAT’s contract research labs produce kilogram quantities of cGMP API utilizing a specially trained, GMP manufacturing team that operates under the USFDA Guidelines for Bulk Pharmaceutical Chemicals (BPC), and is backed by a comprehensive documentation system.
BNOAT screens compounds for anti-cancer activity using the same techniques as the National Cancer Institute’s Developmental Therapeutics Program (DTP).
Additionally, BNOAT has developed analytical methods validated in accordance with the International Conference on Harmonization Guidelines (ICH Q2B, Validation of Analytical Procedures) used in the characterization of nitric oxide donor compounds as well as cobalamins.
BNOAT’s long-term goals are to advance the clinical development of tumor-targeting, non-toxic anti-cancer agents with the goal of significantly improving the standard of care in both cancer treatment and prevention worldwide in both humans and animals.
Targeted delivery of nitric oxide